Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
Department of Pharmacology, University of Maryland School of Medicine, Baltimore, MD, USA.
Mol Psychiatry. 2018 Apr;23(4):801-811. doi: 10.1038/mp.2017.255. Epub 2018 Mar 13.
Clinical studies have demonstrated that a single sub-anesthetic dose of the dissociative anesthetic ketamine induces rapid and sustained antidepressant actions. Although this finding has been met with enthusiasm, ketamine's widespread use is limited by its abuse potential and dissociative properties. Recent preclinical research has focused on unraveling the molecular mechanisms underlying the antidepressant actions of ketamine in an effort to develop novel pharmacotherapies, which will mimic ketamine's antidepressant actions but lack its undesirable effects. Here we review hypotheses for the mechanism of action of ketamine as an antidepressant, including synaptic or GluN2B-selective extra-synaptic N-methyl-D-aspartate receptor (NMDAR) inhibition, inhibition of NMDARs localized on GABAergic interneurons, inhibition of NMDAR-dependent burst firing of lateral habenula neurons, and the role of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor activation. We also discuss links between ketamine's antidepressant actions and downstream mechanisms regulating synaptic plasticity, including brain-derived neurotrophic factor (BDNF), eukaryotic elongation factor 2 (eEF2), mechanistic target of rapamycin (mTOR) and glycogen synthase kinase-3 (GSK-3). Mechanisms that do not involve direct inhibition of the NMDAR, including a role for ketamine's (R)-ketamine enantiomer and hydroxynorketamine (HNK) metabolites, specifically (2R,6R)-HNK, are also discussed. Proposed mechanisms of ketamine's action are not mutually exclusive and may act in a complementary manner to exert acute changes in synaptic plasticity, leading to sustained strengthening of excitatory synapses, which are necessary for antidepressant behavioral actions. Understanding the molecular mechanisms underpinning ketamine's antidepressant actions will be invaluable for the identification of targets, which will drive the development of novel, effective, next-generation pharmacotherapies for the treatment of depression.
临床研究表明,单次亚麻醉剂量的分离麻醉剂氯胺酮可快速且持续地产生抗抑郁作用。尽管这一发现令人兴奋,但氯胺酮的广泛应用受到其滥用潜力和分离特性的限制。最近的临床前研究集中在阐明氯胺酮抗抑郁作用的分子机制,以努力开发新的药物治疗方法,这些方法将模拟氯胺酮的抗抑郁作用,但缺乏其不良作用。在这里,我们综述了氯胺酮作为抗抑郁药的作用机制的假说,包括突触或 GluN2B 选择性的突触外 N-甲基-D-天冬氨酸受体(NMDAR)抑制、抑制 GABA 能中间神经元上的 NMDAR、抑制外侧缰核神经元的 NMDAR 依赖性爆发放电,以及 α-氨基-3-羟基-5-甲基-4-异恶唑丙酸受体激活的作用。我们还讨论了氯胺酮的抗抑郁作用与调节突触可塑性的下游机制之间的联系,包括脑源性神经营养因子(BDNF)、真核延伸因子 2(eEF2)、雷帕霉素靶蛋白(mTOR)和糖原合成酶激酶-3(GSK-3)。还讨论了不涉及 NMDAR 直接抑制的机制,包括氯胺酮的(R)-氯胺酮对映异构体和羟基去甲氯胺酮(HNK)代谢物的作用,特别是(2R,6R)-HNK。氯胺酮作用的拟议机制并非相互排斥,可能以互补的方式发挥作用,导致突触可塑性的急性变化,从而持续增强兴奋性突触,这是抗抑郁行为作用所必需的。了解氯胺酮抗抑郁作用的分子机制对于确定靶点至关重要,这将推动开发新的、有效的、下一代抗抑郁药物治疗方法。